Comparable Clinical Outcomes With Paclitaxel- and Sirolimus-Eluting Stents in Unrestricted Contemporary Practice
John Cosgrave, MD*,
Gloria Melzi, MD*, ,
Simon Corbett, PhD*,
Giuseppe G.L. Biondi-Zoccai, MD ,
Pierfrancesco Agostoni, MD ,
Rade Babic, MD*,
Flavio Airoldi, MD*,,
Alaide Chieffo, MD,
Giuseppe M. Sangiorgi, MD*,
Matteo Montorfano, MD,
Iassen Michev, MD*,,
Mauro Carlino, MD and
Antonio Colombo, MD, FACC*,,*
* EMO Centro Cuore Columbus, Milan, Italy
San Raffaele Scientific Institute, Milan, Italy
Abano Terme Hospital, Abano Terme, Italy
Antwerp Cardiovascular Institute, AZ Middelheim, Antwerp, Belgium.
View larger version (29K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Distribution of Late Loss of Both SES and PES
(A) Distribution of late loss of sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) for the total cohort. Late loss was not normally distributed (p = 0.0001) and was higher in the PES group: 0.45 mm (interquartile ratio [IQR] 0.07 to 0.99) compared with 0.23 mm (IQR –0.02 to 0.69) after SES, p = 0.0001. (B) Distribution of late loss of both SES and PES for nonrestenotic lesions. Late loss was normally distributed and was significantly higher in the PES group: 0.32 ± 0.55 mm compared with 0.06 ± 0.52 mm, p = 0.0001. (C) Distribution of late loss of both SES and PES for restenotic lesions. Late loss was normally distributed, and there was no difference in late loss between the 2 groups: PES 1.78 ± 0.72 mm compared with SES 1.7 ± 0.69 mm, p = 0.39.
|
|
View larger version (13K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Distribution of Late Loss of Both SES and PES for the Total Cohort, Demonstrating the Area of Overlap for the Nonrestenotic and Restenotic Lesions
Abbreviations as in Figure 1.
|
|
|
